| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥45.1B | ¥44.1B | +2.3% |
| Operating Income | ¥1.9B | ¥0.1B | -96.0% |
| Ordinary Income | ¥1.5B | ¥5.2B | -71.1% |
| Net Income | ¥-0.6B | ¥3.1B | -119.9% |
| ROE | -0.6% | 2.8% | - |
FY2025 Q3 cumulative results: Revenue 45.1B yen (YoY +2.3%), Operating Income 1.9B yen (prior period 0.1B yen), Ordinary Income 1.5B yen (YoY -71.1%), Net Income -0.6B yen (YoY -119.9%, turning to loss). Despite modest revenue growth, profitability deteriorated sharply with net income falling into the red primarily due to an exceptionally high effective tax rate of approximately 133.6%. Operating margin of 4.3% remains below prior levels, while an unusual tax burden of 2.5B yen relative to profit before tax of 1.8B yen compressed bottom-line results. Non-operating items included FX gains of 5.7B yen and interest expense of 0.8B yen. The company maintained its full-year guidance of revenue 61.0B yen and operating income 2.4B yen, implying significant Q4 improvement is required.
Revenue increased 2.3% YoY to 45.1B yen, driven primarily by the HealthCare segment which grew 7.6% to 35.7B yen, offsetting a 7.7% decline in Plastic Products segment revenue to 8.9B yen. The HealthCare segment accounts for 79.2% of total revenue and represents the core business. Gross profit of 12.0B yen reflected a gross margin of 26.6%, indicating stable manufacturing profitability. However, SG&A expenses of 10.1B yen consumed 22.3% of revenue, resulting in operating income of only 1.9B yen with an operating margin of 4.3%.
From operating income to ordinary income, non-operating factors included substantial FX gains of 5.7B yen (recorded in non-operating income), dividend income of 0.3B yen, offset by interest expense of 0.8B yen, resulting in net non-operating income of approximately -0.4B yen and ordinary income of 1.5B yen. Extraordinary items comprised a gain on sale of assets of 1.0B yen and loss on disposal of 0.4B yen, contributing net 0.3B yen. Profit before tax reached 1.8B yen, but an exceptionally high income tax expense of 2.5B yen (effective tax rate 133.6%) drove net income attributable to parent to -0.3B yen, representing a -0.6B yen consolidated net loss after adjusting for non-controlling interests of -0.3B yen.
The revenue up/profit down pattern is evident, characterized by modest top-line growth but severe bottom-line deterioration driven by elevated SG&A expenses and abnormal tax burden that overwhelmed operational gains.
HealthCare segment generated revenue of 35.7B yen (YoY +7.6%) with operating income of 6.2B yen and an operating margin of 17.5%, representing the core business with 79.2% revenue share. This segment demonstrated strong profitability and continued growth momentum. Plastic Products segment recorded revenue of 8.9B yen (YoY -7.7%) with an operating loss of 0.2B yen (margin -2.4%), though the loss narrowed from -0.5B yen in the prior period (-52.4B yen segment profit vs -21.5B yen current period), indicating operational improvement despite revenue headwinds. The significant margin differential between segments (17.5% vs -2.4%) underscores HealthCare as the profit engine while Plastic Products remains in restructuring phase. Corporate and other unallocated costs of 3.7B yen reduced consolidated operating income to 1.9B yen.
[Profitability] ROE of -0.6% turned negative from prior period levels, driven by net profit margin of -0.6% (net loss of 0.6B yen on revenue of 45.1B yen). Operating margin of 4.3% declined substantially, reflecting elevated SG&A expense ratio of 22.3% and pressure on operating leverage. Gross margin of 26.6% remained relatively stable. [Cash Quality] Cash and deposits of 21.0B yen provide coverage of 0.37x against short-term debt of 56.2B yen, indicating constrained liquidity. The company holds investment securities of 13.0B yen. [Investment Efficiency] Total asset turnover of 0.240 (calculated as 45.1B yen revenue / 187.9B yen average total assets) remains low, while financial leverage stands at 1.69x (total assets 187.9B yen / equity 111.0B yen). [Financial Health] Equity ratio of 59.1% indicates solid capitalization. Current ratio of 93.7% (current assets 66.0B yen / current liabilities 70.4B yen) falls below 1.0x, signaling short-term liquidity pressure. Debt-to-equity ratio of 0.51x (interest-bearing debt 56.6B yen / equity 111.0B yen) remains moderate, though debt structure is heavily weighted toward short-term borrowings.
Cash and deposits increased modestly from 20.6B yen to 21.0B yen YoY, despite net income turning negative, reflecting other comprehensive income contributions and balance sheet adjustments. Trade receivables increased 27.9% YoY to 11.1B yen while inventories rose to 22.8B yen, indicating working capital absorption that constrains cash generation. Trade payables decreased to 2.0B yen, suggesting reduced supplier credit utilization. Short-term borrowings of 56.2B yen represent 79.8% of current liabilities, indicating heavy reliance on short-term debt financing. The cash position of 21.0B yen provides only 0.37x coverage of short-term debt, warranting close monitoring of refinancing capacity. Property, plant and equipment increased to 107.6B yen, while long-term loans decreased sharply from 1.4B yen to 0.4B yen, suggesting debt structure shifted from long-term to short-term. Investment securities increased 33.8% to 13.0B yen, contributing to comprehensive income through valuation gains.
Operating income of 1.9B yen compared to ordinary income of 1.5B yen reflects net non-operating expense of approximately 0.4B yen, comprised primarily of interest expense of 0.8B yen partially offset by dividend income of 0.3B yen. The reported FX gains of 5.7B yen appear to be included within non-operating income line items, contributing to ordinary income though specific allocation is unclear. Non-operating items represent approximately 1.2% of revenue and include both recurring elements (interest, dividends) and potentially volatile FX components. Extraordinary items totaling net 0.3B yen (gain on asset sale 1.0B yen less disposal loss 0.4B yen) are clearly non-recurring and should be excluded from run-rate earnings assessment. The most significant earnings quality concern stems from the income tax expense of 2.5B yen against profit before tax of 1.8B yen, yielding an effective tax rate of 133.6%, far exceeding statutory rates and indicating deferred tax adjustments or non-deductible items that distort reported earnings. Without operating cash flow disclosure for the quarterly period, direct verification of earnings quality through cash conversion is not possible, though the substantial increase in receivables and inventories suggests working capital consumption may be constraining cash generation relative to reported profits.
Progress against full-year guidance shows revenue at 73.9% (45.1B yen actual / 61.0B yen forecast), operating income at 80.8% (1.9B yen / 2.4B yen), and ordinary income at 106.4% (1.5B yen / 1.4B yen forecast), while net income remains negative at -0.6B yen against forecast of 0.5B yen. At Q3 (75% through the fiscal year), revenue progress of 73.9% tracks slightly below schedule, suggesting modest Q4 growth. Operating income progress of 80.8% appears ahead of pace, though this reflects Q3 cumulative performance and requires Q4 validation. The company maintained its guidance without revision this quarter, implying management confidence in Q4 recovery to achieve full-year net income of 0.5B yen despite Q3 cumulative loss. The forecast assumes Q4 will generate approximately 15.9B yen revenue and 0.5B yen operating income, with critical improvement required in effective tax rate and bottom-line conversion. Given the abnormal Q3 tax burden, achieving positive full-year net income of 0.5B yen requires both operational execution and normalization of tax factors in Q4.
The company forecasts an annual dividend of 10.00 yen per share for the full year. With net income forecast of 0.5B yen (50M yen) and forecasted EPS of 4.61 yen, the implied full-year payout ratio would be 217% (10.00 yen dividend / 4.61 yen EPS), significantly exceeding 100% and indicating dividend payment would exceed forecasted earnings. Based on Q3 cumulative results with net loss of 0.6B yen, the current dividend commitment cannot be supported by earnings and would require funding from retained earnings or other capital resources. No share buyback activity was disclosed for the period. The sustainability of the 10.00 yen dividend depends critically on achieving the full-year earnings forecast and Q4 recovery, as well as adequate cash reserves of 21.0B yen to fund the approximately 1.1B yen annual dividend payment (10.00 yen x 10.9M shares outstanding).
First, short-term liquidity risk is elevated with current ratio of 93.7% and cash coverage of only 0.37x against short-term debt of 56.2B yen, concentrated refinancing risk given 79.8% of current liabilities are short-term borrowings. Second, working capital deterioration evidenced by receivables increasing 27.9% YoY to 11.1B yen and inventories at 22.8B yen indicates collection delays and inventory accumulation that constrain cash conversion and may signal demand or operational inefficiencies. Third, abnormal tax burden with effective tax rate of 133.6% created by income tax expense of 2.5B yen against profit before tax of 1.8B yen represents significant earnings volatility risk if deferred tax adjustments or non-deductible items persist in future periods.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE -0.6% significantly underperforms the manufacturing industry median of 5.8% (2025-Q3, n=105), placing the company in the bottom quartile. Operating margin of 4.3% trails the industry median of 8.9% (IQR: 5.4%-12.7%), indicating below-median operational efficiency. Net profit margin of -0.6% (cumulative Q3 basis) compares unfavorably to industry median of 6.5% (IQR: 3.3%-9.4%).
Financial Health: Equity ratio of 59.1% aligns closely with industry median of 63.8% (IQR: 49.1%-74.8%), demonstrating solid capitalization. However, current ratio of 93.7% falls substantially below industry median of 2.87x (IQR: 2.13x-3.84x), highlighting acute short-term liquidity pressure relative to peers.
Efficiency: Total asset turnover of 0.240 lags the industry median of 0.56 (IQR: 0.41-0.65), reflecting lower asset utilization. Financial leverage of 1.69x is moderately above industry median of 1.53x (IQR: 1.31-1.86).
Growth: Revenue growth of 2.3% YoY is consistent with industry median of 2.8% (IQR: -1.5%-8.8%), indicating in-line top-line performance.
The company demonstrates capital structure strength but materially underperforms on profitability metrics and liquidity positioning relative to manufacturing sector peers.
※ Industry: Manufacturing (105 companies), Comparison: 2025-Q3 period, Source: Proprietary analysis
First, the sharp profitability deterioration driven by abnormal effective tax rate of 133.6% and elevated SG&A expenses compressing operating margin to 4.3% represents a critical earnings quality concern requiring immediate management attention and transparency on tax normalization plans. Second, short-term liquidity constraints with current ratio of 93.7% and cash coverage of only 0.37x against 56.2B yen short-term debt create refinancing risk that must be addressed through working capital optimization, debt restructuring, or alternative funding. Third, the divergence between segment performance with HealthCare achieving 17.5% margins while Plastic Products operates at -2.4% margins highlights portfolio optimization opportunity and the need for strategic assessment of underperforming operations. Fourth, dividend sustainability at 10.00 yen per share faces significant challenge given Q3 cumulative net loss and forecasted payout ratio exceeding 200%, requiring validation of Q4 recovery and cash adequacy to maintain shareholder returns.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.